375 related articles for article (PubMed ID: 30580091)
1. Incidence Trends of Gastroenteropancreatic Neuroendocrine Tumors in the United States.
Lee MR; Harris C; Baeg KJ; Aronson A; Wisnivesky JP; Kim MK
Clin Gastroenterol Hepatol; 2019 Oct; 17(11):2212-2217.e1. PubMed ID: 30580091
[TBL] [Abstract][Full Text] [Related]
2. Epidemiologic Trends of and Factors Associated With Overall Survival for Patients With Gastroenteropancreatic Neuroendocrine Tumors in the United States.
Xu Z; Wang L; Dai S; Chen M; Li F; Sun J; Luo F
JAMA Netw Open; 2021 Sep; 4(9):e2124750. PubMed ID: 34554237
[TBL] [Abstract][Full Text] [Related]
3. Survival of Patients With Gastroenteropancreatic Neuroendocrine Tumors and Diabetes Mellitus.
Thapi S; Baeg K; Kim MK; Gallagher EJ
Pancreas; 2021 Oct; 50(9):1293-1297. PubMed ID: 34860814
[TBL] [Abstract][Full Text] [Related]
4. Increasing incidence of duodenal neuroendocrine tumors: Incidental discovery of indolent disease?
Fitzgerald TL; Dennis SO; Kachare SD; Vohra NA; Zervos EE
Surgery; 2015 Aug; 158(2):466-71. PubMed ID: 26013986
[TBL] [Abstract][Full Text] [Related]
5. Recent epidemiology of patients with gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NEN) in Japan: a population-based study.
Masui T; Ito T; Komoto I; Uemoto S;
BMC Cancer; 2020 Nov; 20(1):1104. PubMed ID: 33189127
[TBL] [Abstract][Full Text] [Related]
6. Epidemiological features of gastroenteropancreatic neuroendocrine tumors in Chengdu city with a population of 14 million based on data from a single institution.
Guo LJ; Wang CH; Tang CW
Asia Pac J Clin Oncol; 2016 Sep; 12(3):284-8. PubMed ID: 27170574
[TBL] [Abstract][Full Text] [Related]
7. Clinically detected gastroenteropancreatic neuroendocrine tumors are on the rise: epidemiological changes in Germany.
Scherübl H; Streller B; Stabenow R; Herbst H; Höpfner M; Schwertner C; Steinberg J; Eick J; Ring W; Tiwari K; Zappe SM
World J Gastroenterol; 2013 Dec; 19(47):9012-9. PubMed ID: 24379626
[TBL] [Abstract][Full Text] [Related]
8. Epidemiological Data and Treatment of Gastroenteropancreatic Neuroendocrine Neoplasms: Insights From Tertiary Referral Hospitals in Latvia.
Ptasnuka M; Ozolins A; Narbuts Z; Truskovs A; Sperga M; Plaudis H
World J Surg; 2020 Feb; 44(2):585-593. PubMed ID: 31605174
[TBL] [Abstract][Full Text] [Related]
9. Incidence of gastroenteropancreatic neuroendocrine tumours: a systematic review of the literature.
Fraenkel M; Kim M; Faggiano A; de Herder WW; Valk GD;
Endocr Relat Cancer; 2014 Jun; 21(3):R153-63. PubMed ID: 24322304
[TBL] [Abstract][Full Text] [Related]
10. The epidemiology of gastroenteropancreatic neuroendocrine tumors.
Lawrence B; Gustafsson BI; Chan A; Svejda B; Kidd M; Modlin IM
Endocrinol Metab Clin North Am; 2011 Mar; 40(1):1-18, vii. PubMed ID: 21349409
[TBL] [Abstract][Full Text] [Related]
11. Peritoneal Metastases from Gastroenteropancreatic Neuroendocrine Tumors: Incidence, Risk Factors and Prognosis.
Madani A; Thomassen I; van Gestel YRBM; van der Bilt JDW; Haak HR; de Hingh IHJT; Lemmens VEPP
Ann Surg Oncol; 2017 Aug; 24(8):2199-2205. PubMed ID: 28204963
[TBL] [Abstract][Full Text] [Related]
12. Incidence trends of lung and gastroenteropancreatic neuroendocrine neoplasms in Switzerland.
Alwan H; La Rosa S; Andreas Kopp P; Germann S; Maspoli-Conconi M; Sempoux C; Bulliard JL
Cancer Med; 2020 Dec; 9(24):9454-9461. PubMed ID: 33078908
[TBL] [Abstract][Full Text] [Related]
13. Trends in diagnosis of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in India: A report of multicenter data from a web-based registry.
Palepu J; Shrikhande SV; Bhaduri D; Shah RC; Sirohi B; Chhabra V; Dhar P; Sastry R; Sikora S
Indian J Gastroenterol; 2017 Nov; 36(6):445-451. PubMed ID: 29457213
[TBL] [Abstract][Full Text] [Related]
14. Chilean Registry for Neuroendocrine Tumors: A Latin American Perspective.
Pinto MP; Muñoz Medel M; Carrillo D; Retamal IN; Bravo ML; Valenzuela Y; Nervi B; Sánchez C; Galindo H; Ibañez C; Peña J; Balmaceda C; Madrid J; Briones J; Torres J; Nilo F; Guarda FJ; Quintana JC; Orellana P; Mondaca S; Acevedo F; Vicentini D; Cordova-Delgado M; Owen GI; Garrido M
Horm Cancer; 2019 Feb; 10(1):3-10. PubMed ID: 30465145
[TBL] [Abstract][Full Text] [Related]
15. Gastroenteropancreatic neuroendocrine neoplasms: current development, challenges, and clinical perspectives.
Zhang XB; Fan YB; Jing R; Getu MA; Chen WY; Zhang W; Dong HX; Dakal TC; Hayat A; Cai HJ; Ashrafizadeh M; Abd El-Aty AM; Hacimuftuoglu A; Liu P; Li TF; Sethi G; Ahn KS; Ertas YN; Chen MJ; Ji JS; Ma L; Gong P
Mil Med Res; 2024 Jun; 11(1):35. PubMed ID: 38835066
[TBL] [Abstract][Full Text] [Related]
16. Epidemiology, Incidence, and Prevalence of Neuroendocrine Neoplasms: Are There Global Differences?
Das S; Dasari A
Curr Oncol Rep; 2021 Mar; 23(4):43. PubMed ID: 33719003
[TBL] [Abstract][Full Text] [Related]
17. Site-specific trends in gastroenteropancreatic neuroendocrine neoplasms in Bavaria, Germany.
Grundmann N; Voigtländer S; Hakimhashemi A; Pape UF; Meyer M; Müller-Nordhorn J
Cancer Med; 2023 Oct; 12(19):19949-19958. PubMed ID: 37737059
[TBL] [Abstract][Full Text] [Related]
18. Time from first tumor manifestation to diagnosis in patients with GEP-NET: Results from a large German tertiary referral center.
Koch C; Koca E; Filmann N; Husmann G; Bojunga J
Medicine (Baltimore); 2021 Sep; 100(37):e27276. PubMed ID: 34664885
[TBL] [Abstract][Full Text] [Related]
19. Localized high-grade gastroenteropancreatic neuroendocrine tumors: Defining prognostic and therapeutic factors for a disease of increasing clinical significance.
Mosquera C; Koutlas NJ; Fitzgerald TL
Eur J Surg Oncol; 2016 Oct; 42(10):1471-7. PubMed ID: 27528467
[TBL] [Abstract][Full Text] [Related]
20. Initial impact of a systematic multidisciplinary approach on the management of patients with gastroenteropancreatic neuroendocrine tumor.
Tamagno G; Sheahan K; Skehan SJ; Geoghegan JG; Fennelly D; Collins CD; Maguire D; Traynor O; Brophy DP; Cantwell C; Swan N; McGowan L; O'Toole D; O'Shea D
Endocrine; 2013 Oct; 44(2):504-9. PubMed ID: 23471696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
